{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eligibility+Screening&page=2", "query": { "intervention": "Eligibility Screening", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eligibility+Screening&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T16:32:52.367Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02528500", "title": "GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Thoracoabdominal Aortic Aneurysm" ], "interventions": [ { "name": "GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "W.L.Gore & Associates", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-11", "completion_date": "2023-02", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 6, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Lebanon, New Hampshire + 3 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02528500" }, { "nct_id": "NCT03517007", "title": "The DETOURS Trial: De-escalating Empiric Treatment: Opting Out of Rx for Selected Patients With Suspected Sepsis - Opt-Out Protocol Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Antibiotic Stewardship" ], "interventions": [ { "name": "Opt-Out Protocol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 762, "start_date": "2018-09-12", "completion_date": "2020-08-10", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Fayetteville, Georgia • Newnan, Georgia + 6 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Fayetteville", "state": "Georgia" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517007" }, { "nct_id": "NCT06133816", "title": "Lung Cancer Screening Eligibility Assessment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Framed Introductory Message A", "type": "BEHAVIORAL" }, { "name": "Framed Introductory Message B", "type": "BEHAVIORAL" }, { "name": "Framed Introductory Message C", "type": "BEHAVIORAL" }, { "name": "Framed Tobacco Use Message A", "type": "BEHAVIORAL" }, { "name": "Framed Tobacco Use Message B", "type": "BEHAVIORAL" }, { "name": "Financial Incentive", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 6125, "start_date": "2023-07-31", "completion_date": "2024-01-31", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06133816" }, { "nct_id": "NCT03125239", "title": "Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Adult Acute Myeloid Leukemia", "Refractory Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Merestinib", "type": "DRUG" }, { "name": "LY2874455", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacqueline Garcia, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-08-10", "completion_date": "2020-06-01", "has_results": false, "last_update_posted_date": "2020-06-30", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03125239" }, { "nct_id": "NCT04698681", "title": "NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer", "Non-squamous Non-small-cell Lung Cancer", "Non-Squamous Non-Small Cell Neoplasm of Lung", "KEAP1 Gene Mutation", "NRF2 Mutation", "NFE2L2 Gene Mutation" ], "interventions": [], "intervention_types": [], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-01-19", "completion_date": "2022-02-09", "has_results": false, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 63, "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04698681" }, { "nct_id": "NCT01671735", "title": "VA Diabetes Prevention: Epidemiology of Pre-Diabetes and Implementation Pilot", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Survey", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2012-09", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2012-10-15", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01671735" }, { "nct_id": "NCT06930352", "title": "Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ziftomenib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Uma Borate", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2026-10-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06930352" }, { "nct_id": "NCT04199117", "title": "Health Systems Reach Interventions Project", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Smoking, Cigarette", "Smoking Cessation" ], "interventions": [ { "name": "Varenicline", "type": "DRUG" }, { "name": "Combination nicotine patch and nicotine mini-lozenge treatment", "type": "DRUG" }, { "name": "Monetary incentives for initiating treatment", "type": "BEHAVIORAL" }, { "name": "Automated tailored outreach", "type": "BEHAVIORAL" }, { "name": "Care management", "type": "BEHAVIORAL" }, { "name": "Wisconsin Tobacco Quit Line referral", "type": "OTHER" }, { "name": "Primary care provider referral", "type": "OTHER" }, { "name": "Untailored outreach", "type": "BEHAVIORAL" }, { "name": "Multiple smoking cessation coaching calls", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2020-03-11", "completion_date": "2024-10-16", "has_results": true, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04199117" }, { "nct_id": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Acute Myeloid Leukemia, Myelodysplasia-Related", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Luspatercept", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olutasidenib", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2024-06-18", "completion_date": "2029-05-15", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 337, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564390" }, { "nct_id": "NCT04388735", "title": "Multiple Myeloma (MM) Quality of Life (QOL) Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma", "Quality of Life", "Symptom, Behavioral" ], "interventions": [ { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2020-06", "completion_date": "2022-05-16", "has_results": false, "last_update_posted_date": "2020-05-14", "last_synced_at": "2026-09-23T16:32:52.367Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04388735" } ] }